Subscribe

Fosun

Fosun
SSE
HKEX

Fosun Pharma is a pharmaceutical company.

OVERVIEW

Categories
Healthcare, Medical Technology, Medical Service, Vitro Diagnosis, Pharmaceutical sales, Medical Instrument, Medical, Pharmaceutical R&D
HQ location
Shanghai
Founded date
May. 31, 1995
IPO date
Aug. 7, 1998
Legal name
Shanghai Fosun Pharmaceutical Co., Ltd.
Shanghai Fosun Pharmaceutical (Group) Co., Ltd. (“Fosun Pharma”), a leading healthcare company in China,which was established in 1994 ,has been listed on Shanghai Stock Exchange since August 1998 and on the Main Board of the Stock Exchange of Hong Kong Limited ( stock code: 600196-SH,02196-HK). Specializing in modern biopharmaceutical and healthcare industry, Fosun Pharma has captured opportunities within the rapidly developing Chinese healthcare industry as well as from the globalization of Chinese healthcare companies in general. Fosun Pharma's operations strategically cover several important segments of the healthcare industry value-chain, including: pharmaceutical manufacturing, distribution and retail. In particular, the Company has a leading market position and unmatched advantages in pharmaceutical distribution and retail, healthcare services, diagnostic products and medical devices, and maintains a strong focus on research and development, and manufacturing. As one of the largest healthcare companies in China, Fosun Pharma enjoys a competitive advantage in research and development, innovation, marketing, integration of mergers and acquisitions, as well as human resources. As a result of its focus on innovation, research and development, Fosun Pharma maintains a highly capable international R&D team with operations in Shanghai and Chongqing and United States in addition to its National Recognized Enterprise Technology Centre. Fosun Pharma's research and development activities cover therapeutic areas such as metabolism and alimentary tract, the cardiovascular system, anti-tumor,central nervous system and anti-infective drug. The Company has market-leading products in China in such segments as liver diseases, diabetes, tuberculosis and diagnostic products; and is the leading provider of anti-malaria medicines globally. While focusing on pharmaceutical manufacturing, Fosun Pharma has built a leading position in diagnostic products and medical devices while actively developing its presence in healthcare services, where it has a solid foundation for domestic high-end and specialty services. Fosun Pharma is the second largest shareholder of Sinopharm, China's largest pharmaceutical distributor. Fosun Pharma strongly believes in the principle of sustainable development and has incorporated social responsibility into its long-term business strategy. In full recognition of its social role, Fosun Pharma endeavors to meet the needs of its community, customers, employees and shareholders throughout conducting its business and its future development. With its commitment to innovation for good health and creating a better future, Fosun Pharma remains on its mission to promote health and well-being. The Company's strategic development approach of “Organic Growth, Coupled with M&A and Integration” allows it to continue to enhance creativity and service, drive integration and achieve global capabilities. As a result, Fosun Pharma will emerge with effective operation, world-class management, sound investments and as a leading provider of healthcare products and services.
600196:SSE 02196:HKEX
Transaction date
May. 29, 2020
52-week high
CNY 38.88
52-week low
CNY 22.30
Volume
728,447,291
Open
CNY 30.36
Close
CNY 30.75
P/E
-
Market cap
CNY 78.81 billion
Transaction date
Jun. 2, 2020
52-week high
HKD 31.10
52-week low
HKD 18.98
Volume
88,404,543
Open
HKD 24.75
Close
HKD 24.75
P/E
17.11
Market cap
HKD 63.43 billion

ANALYSIS

The new crown epidemic hits the world, who will lead the vaccine development competition?

The development of the new crown vaccine has become an area where countries are vying to win the jackpot.

Mar. 21, 2020 · Fosun

NDA application for Fosun Katekilyrensai injection is accepted, and domestic CAR-T drugs are expected to be marketed

In August 2018, CDE approved Fosun Kate's IND application; in October of the same year, it passed the approval of the Genetics Office and officially launched the FKC876 clinical bridging trial. From approval of the IND to completion of clinical trials, Fosun Kate only took more than a year.

Feb. 26, 2020 · Fosun

Hengrui VS Fosun: Different Strategies Create Absolute Leaders and Evergreens in the Big Health Field

The completely different growth path between Hengrui and Fosun fully reflects the core role of strategic thinking in the development of the enterprise, and the strategic thinking is closely related to the early resume of the founder of the company. The "gene" of the founder largely determines the "gene" of the enterprise.

Feb. 22, 2020 · Fosun

REPORTS

Fosun Pharma (600196.SH): Cooperation with BioNTech to lay out the field of mRNA vaccines

The 2019-2021 EPS is expected to be 1.56, 1.46, and 1.78 yuan, corresponding to 17 times PE in 2019 (19 times PE in 2020) based on the closing price on March 16, 2020

Mar. 17, 2020 · Fosun

Fosun Pharma (600196.SH) / Fosun Pharma (2196.HK): CAR-T submits marketing application to lead domestic cellular immunotherapy

The 20-year EPS forecast is 1.42 yuan (the original forecast was 1.45 yuan). Maintaining the 19/21 EPS forecast is 1.20 / 1.72 yuan. The current price of A shares corresponds to 19/21 PE of 23/20/16. Rating; H-share current price corresponds to 19/21 PE at 18/15/12 times

Feb. 27, 2020 · Fosun
  • Company Details
  • Related Companies
  • EO Analysis
Overview
Categories
Healthcare, Medical Technology, Medical Service, Vitro Diagnosis, Pharmaceutical sales, Medical Instrument, Medical, Pharmaceutical R&D
HQ location
Shanghai
Founded date
May. 31, 1995
IPO date
Aug. 7, 1998
Legal name
Shanghai Fosun Pharmaceutical Co., Ltd.
Shanghai Fosun Pharmaceutical (Group) Co., Ltd. (“Fosun Pharma”), a leading healthcare company in China,which was established in 1994 ,has been listed on Shanghai Stock Exchange since August 1998 and on the Main Board of the Stock Exchange of Hong Kong Limited ( stock code: 600196-SH,02196-HK). Specializing in modern biopharmaceutical and healthcare industry, Fosun Pharma has captured opportunities within the rapidly developing Chinese healthcare industry as well as from the globalization of Chinese healthcare companies in general. Fosun Pharma's operations strategically cover several important segments of the healthcare industry value-chain, including: pharmaceutical manufacturing, distribution and retail. In particular, the Company has a leading market position and unmatched advantages in pharmaceutical distribution and retail, healthcare services, diagnostic products and medical devices, and maintains a strong focus on research and development, and manufacturing. As one of the largest healthcare companies in China, Fosun Pharma enjoys a competitive advantage in research and development, innovation, marketing, integration of mergers and acquisitions, as well as human resources. As a result of its focus on innovation, research and development, Fosun Pharma maintains a highly capable international R&D team with operations in Shanghai and Chongqing and United States in addition to its National Recognized Enterprise Technology Centre. Fosun Pharma's research and development activities cover therapeutic areas such as metabolism and alimentary tract, the cardiovascular system, anti-tumor,central nervous system and anti-infective drug. The Company has market-leading products in China in such segments as liver diseases, diabetes, tuberculosis and diagnostic products; and is the leading provider of anti-malaria medicines globally. While focusing on pharmaceutical manufacturing, Fosun Pharma has built a leading position in diagnostic products and medical devices while actively developing its presence in healthcare services, where it has a solid foundation for domestic high-end and specialty services. Fosun Pharma is the second largest shareholder of Sinopharm, China's largest pharmaceutical distributor. Fosun Pharma strongly believes in the principle of sustainable development and has incorporated social responsibility into its long-term business strategy. In full recognition of its social role, Fosun Pharma endeavors to meet the needs of its community, customers, employees and shareholders throughout conducting its business and its future development. With its commitment to innovation for good health and creating a better future, Fosun Pharma remains on its mission to promote health and well-being. The Company's strategic development approach of “Organic Growth, Coupled with M&A and Integration” allows it to continue to enhance creativity and service, drive integration and achieve global capabilities. As a result, Fosun Pharma will emerge with effective operation, world-class management, sound investments and as a leading provider of healthcare products and services.
600196:SSE
Transaction date
May. 29, 2020
52-week high
CNY 38.88
52-week low
CNY 22.30
Volume
728,447,291
Open
CNY 30.36
Close
CNY 30.75
P/E
-
Market cap
CNY 78.81 billion
02196:HKEX
Transaction date
Jun. 2, 2020
52-week high
HKD 31.10
52-week low
HKD 18.98
Volume
88,404,543
Open
HKD 24.75
Close
HKD 24.75
P/E
17.11
Market cap
HKD 63.43 billion
Analysis

The new crown epidemic hits the world, who will lead the vaccine development competition?

The development of the new crown vaccine has become an area where countries are vying to win the jackpot.

Mar. 21, 2020 · Fosun

NDA application for Fosun Katekilyrensai injection is accepted, and domestic CAR-T drugs are expected to be marketed

In August 2018, CDE approved Fosun Kate's IND application; in October of the same year, it passed the approval of the Genetics Office and officially launched the FKC876 clinical bridging trial. From approval of the IND to completion of clinical trials, Fosun Kate only took more than a year.

Feb. 26, 2020 · Fosun

Hengrui VS Fosun: Different Strategies Create Absolute Leaders and Evergreens in the Big Health Field

The completely different growth path between Hengrui and Fosun fully reflects the core role of strategic thinking in the development of the enterprise, and the strategic thinking is closely related to the early resume of the founder of the company. The "gene" of the founder largely determines the "gene" of the enterprise.

Feb. 22, 2020 · Fosun
Reports

Fosun Pharma (600196.SH): Cooperation with BioNTech to lay out the field of mRNA vaccines

The 2019-2021 EPS is expected to be 1.56, 1.46, and 1.78 yuan, corresponding to 17 times PE in 2019 (19 times PE in 2020) based on the closing price on March 16, 2020

Mar. 17, 2020 · Fosun

Fosun Pharma (600196.SH) / Fosun Pharma (2196.HK): CAR-T submits marketing application to lead domestic cellular immunotherapy

The 20-year EPS forecast is 1.42 yuan (the original forecast was 1.45 yuan). Maintaining the 19/21 EPS forecast is 1.20 / 1.72 yuan. The current price of A shares corresponds to 19/21 PE of 23/20/16. Rating; H-share current price corresponds to 19/21 PE at 18/15/12 times

Feb. 27, 2020 · Fosun